Literature DB >> 16254130

Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive/memory T-cell subtypes.

Djordje Atanackovic1, Kristina Pollok, Christiane Faltz, Ina Boeters, Roman Jung, Alexander Nierhaus, Klaus-Michael Braumann, Dieter Kurt Hossfeld, Susanna Hegewisch-Becker.   

Abstract

An activation of the immune system might contribute to the therapeutic effect of whole body hyperthermia (WBH) in cancer patients. We explored immune and endocrine responses in patients undergoing high-temperature WBH. Identical parameters were investigated in a separate group of healthy volunteers undergoing physical exercise to rule out effects of sympathetic activation. Lymphocyte subpopulations, lymphocytic expression of a range of adhesion molecules, and serum concentrations of a variety of hormones and cytokines were assessed in cancer patients undergoing high-temperature (60 min at 41.0-41.8 degrees C) WBH (n = 25) and in a separate group of healthy volunteers (n = 10) performing strenuous physical exercise. WBH induced an increase in human growth hormone (hGH), ACTH, and cortisol as well as in TNF-alpha, IL-6, IL-8, and IL-12R. We observed an increase in natural killer (NK) cells and CD56+ NK T cells shortly after initiation of WBH. In contrast, we found a decrease in T cells expressing L-selectin (CD62L) or alpha4beta7 integrin adhesion molecules mediating homing to lymphatic tissues. Accordingly, we observed a decrease in CD45RA+CCR7+ naive and CD45RA-CCR7+ central memory T cells. Numbers of CD45RA-CCR7- memory effector and CD45RA+CCR7 terminally differentiated T cells, on the other hand, remained unchanged. No comparable changes were observed in the group of healthy volunteers. In conclusion, patients with solid tumors treated with WBH show an increase in NK and NK T cells. In a later phase, plasma concentrations of IL-8, hGH, and cortisol increase, correlated with an influx of neutrophils into the peripheral blood. The alterations in T-cell populations suggest that WBH may induce naive and central-memory T cells to enter lymphatic tissue to await antigen exposure and effector T cells to migrate into peripheral tissues to exert their effector function. Although the exercise group may not be an appropriate control to proof the effect of WBH, these changes were not seen in the healthy volunteers performing physical exercise.

Entities:  

Mesh:

Year:  2005        PMID: 16254130     DOI: 10.1152/ajpregu.00014.2005

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  6 in total

1.  Toward establishment of temperature thresholds for immunological impact of heat exposure in humans.

Authors:  Sarah H Beachy; Elizabeth A Repasky
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

Review 2.  Hyperthermia as an immunotherapy strategy for cancer.

Authors:  Joseph J Skitzki; Elizabeth A Repasky; Sharon S Evans
Journal:  Curr Opin Investig Drugs       Date:  2009-06

Review 3.  Fine-tuning immune surveillance by fever-range thermal stress.

Authors:  Daniel T Fisher; Trupti D Vardam; Jason B Muhitch; Sharon S Evans
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

4.  The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury.

Authors:  Katherine A Radek; Belen Lopez-Garcia; Melanie Hupe; Ingrid R Niesman; Peter M Elias; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2008-01-10       Impact factor: 8.551

5.  Treatment of malignant glioma using hyperthermia.

Authors:  Jiahang Sun; Mian Guo; Hengyuan Pang; Jingtao Qi; Jinwei Zhang; Yunlong Ge
Journal:  Neural Regen Res       Date:  2013-10-15       Impact factor: 5.135

Review 6.  Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.

Authors:  Zihui Li; Jie Deng; Jianhai Sun; Yanling Ma
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.